Skip to main content

-

Technology Guidance - Drug

Abiraterone for treating metastatic prostate cancer Published on 1 October 2020


Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
    Generic abiraterone acetate 250 mg tablet (Abiranat) in line with its registered indications for treating:
    • newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT);
    • metastatic castration-resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated; and
    • metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

    Subsidy status

    Generic abiraterone acetate 250 mg tablet (Abiranat) is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

    SDL subsidy does not apply to proprietary abiraterone acetate 250 mg and 500 mg tablets (Zytiga).

      
    Get Acrobat Readeropens in a new window
    Back to Top